Kurma Growth led a €84m Series B round in Nuclidium.

Kurma Growth, is a private equity growth and expansion fund managed by venture capital firm Kurma Partners led a €84m Series B round in Nuclidium, a clinical-stage radiopharmaceutical company developing a copper-based theranostic platform, with participation from Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.Bank and HighLight Capital. “This significant Series B financing reflects the confidence of our investors in Nuclidium’s vision and the transformative potential for the diagnostic and therapeutic industry in oncology and nuclear medicine. With this backing, we are positioned to accelerate clinical development, broaden patient access globally, and reinforce our commitment to innovation in precision oncology. I am delighted to welcome our new Board and advisory members, whose deep expertise will further strengthen Nuclidium’s leadership in radiopharmaceuticals,” Tony Rosenberg, Nuclidium Board Chairman.